SHANGHAI – Beigene Co. Ltd. is betting its Bruton's tyrosine kinase inhibitor, BGB-3111, has world-class potential and is gearing up for proof-of-concept trials in the U.S. to find out. The company just received approval for its investigational new drug application from the FDA and is beginning to build up its U.S.-based operation to support the upcoming trials.
SHANGHAI – Beigene Co. Ltd. is betting its Bruton's tyrosine kinase inhibitor, BGB-3111, has world-class potential and is gearing up for proof-of-concept trials in the U.S. to find out.
SHANGHAI – Luqa Pharmaceuticals' $15 million series A financing will boost efforts to acquire, develop and commercialize products for Chinese patients in the aesthetics and quality-of-life markets. Products include pharmaceuticals and devices for both the reconstructive and elective plastic surgery market.
SHANGHAI – When Johnson & Johnson (J&J) set up its network of four Innovation Centers in the world's life science hot spots – Boston, California, London and Shanghai – it put into action a global experiment: Could a giant find a way to systematically engage in early stage possibilities in drugs, devices or consumer health with its innovative, entrepreneurial brethren? Having just announced 17 deals across the globe bringing the overall deal total to 200, they have shown if they fail, it won't be for lack of effort.
SHANGHAI – Inside Johnson & Johnson Innovation Center's 17-deal announcement, the Asia Pacific Innovation Center (APIC) shows it has been busy, too, signing four deals in the region: in Japan, Australia, Mainland China and Taiwan.
SHANGHAI – When Johnson & Johnson (J&J) set up its network of five Innovation Centers in the world's life science hot spots – Boston, California, London and Shanghai – it put into action a global experiment: Could a giant find a way to systematically engage in early stage possibilities in drugs, devices or consumer health with its innovative, entrepreneurial brethren? Having just announced 17 deals across the globe bringing the overall deal total to 200, they have shown if they fail, it won't be for lack of effort.
SHANGHAI – Inside Johnson & Johnson Innovation Center's 17-deal announcement, the Asia Pacific Innovation Center (APIC) shows it has been busy, too, signing four deals in the region: in Japan, Australia, Mainland China and Taiwan.
SHANGHAI – New out of the gate, Suzhou Neupharma Co. Ltd., has put its first candidate, RX-108, into clinical trials. Like many companies in China with global ambitions, Neupharma is collecting its first-in-human data in Australia while it waits for its trials to get a green light in China. (See Beigene story this issue.)
